Mandate

Vinge has advised Sveafastigheter in connection with its listing on Nasdaq First North Premier Growth Market

Vinge has advised Sveafastigheter AB (publ) (”Sveafastigheter”) in connection with its listing on Nasdaq First North Premier Growth Market. The prospectus was published on 7 October 2024 and the first day of trading is 18 October 2024.

The offering price was SEK 39.50, corresponding to a market value of Sveafastigheter of approximately SEK 7.9 billion. The offering comprises up to 88,000,000 shares, corresponding to a value of approximately SEK 3.5 billion, provided that the overallotment option is fully exercised.

Sveafastigheter is a real estate company that owns, actively manages and develops residential properties throughout Sweden with a focus on rental apartments in selected growth regions. The property portfolio consists of standing assets, ongoing construction and project development with a total property value of approximately SEK 27.5 billion.

Vinge’s team primarily consisted of Jesper Schönbeck, Rikard Lindahl, Joel Magnusson, Benjamin Vafaeian, Johannes Akyol, Louise Nässén and Filip Magnusson (Capital Markets and Public M&A), Kristoffer Larson and Agnes Pigg (Real Estate), Victor Ericsson, Emelie Svanberg, Ellenor Eckerborn and Marcus Svärd (Corporate Tax), Mikael Ståhl, Kamyar Najmi and William Carlberg Johansson (Banking and Finance).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026